To test the hypothesis, a 24-week, randomized, open-label, parallel-group trial was conducted comparing PEG-Loxe vs. insulin glargine in middle-aged and elderly patients with T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.